Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Interest ReceivablesChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Cash from Financing Activities: 2024-2025

  • Abivax's Cash from Financing Activities fell 148.19% to -$9.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $25.5 million, marking a year-over-year change of. This contributed to the annual value of $30.1 million for FY2024, which is 91.64% down from last year.
  • Latest data reveals that Abivax reported Cash from Financing Activities of -$9.9 million as of Q2 2025, which was down 20.38% from -$8.2 million recorded in Q1 2025.
  • Abivax's Cash from Financing Activities' 5-year high stood at $23.0 million during Q1 2024, with a 5-year trough of -$9.9 million in Q2 2025.
  • In the last 2 years, Abivax's Cash from Financing Activities had a median value of $6.2 million in 2024 and averaged $6.4 million.
  • Data for Abivax's Cash from Financing Activities shows a maximum YoY crashed of 148.19% (in 2025) over the last 5 years.
  • Abivax's Cash from Financing Activities (Quarterly) stood at $20.6 million in 2024, then tumbled by 148.19% to -$9.9 million in 2025.
  • Its Cash from Financing Activities was -$9.9 million in Q2 2025, compared to -$8.2 million in Q1 2025 and $20.6 million in Q2 2024.